Mizuho initiated coverage on shares of FibroGen, Inc (NASDAQ:FGEN) in a research report released on Wednesday, Marketbeat reports. The firm issued a neutral rating and a $61.00 price target on the biopharmaceutical company’s stock.

Other equities analysts have also recently issued reports about the company. Jefferies Group LLC assumed coverage on FibroGen in a report on Monday, July 10th. They set a buy rating and a $50.00 price target on the stock. Leerink Swann reaffirmed an outperform rating and set a $82.00 target price (up from $52.00) on shares of FibroGen in a research report on Tuesday, August 8th. William Blair reaffirmed an outperform rating on shares of FibroGen in a research report on Wednesday, August 9th. Citigroup Inc. upped their target price on FibroGen from $48.00 to $65.00 and gave the stock a top pick rating in a research report on Tuesday, August 8th. Finally, BidaskClub raised FibroGen from a buy rating to a strong-buy rating in a research report on Saturday, June 24th. Two investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The company currently has a consensus rating of Buy and a consensus price target of $65.67.

FibroGen (NASDAQ:FGEN) traded down 2.65% during mid-day trading on Wednesday, hitting $55.20. 723,955 shares of the stock were exchanged. The company’s market capitalization is $3.93 billion. The stock has a 50 day moving average price of $49.78 and a 200 day moving average price of $35.13. FibroGen has a 1-year low of $15.60 and a 1-year high of $60.15.

FibroGen (NASDAQ:FGEN) last posted its quarterly earnings results on Monday, August 7th. The biopharmaceutical company reported ($0.48) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.47) by ($0.01). The business had revenue of $29.00 million for the quarter, compared to the consensus estimate of $34.80 million. FibroGen had a negative return on equity of 64.42% and a negative net margin of 105.59%. On average, equities analysts anticipate that FibroGen will post ($1.81) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “FibroGen, Inc (FGEN) Coverage Initiated by Analysts at Mizuho” was first published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this piece on another publication, it was stolen and reposted in violation of U.S. and international copyright and trademark laws. The original version of this piece can be viewed at https://www.thecerbatgem.com/2017/10/08/fibrogen-inc-fgen-coverage-initiated-by-analysts-at-mizuho.html.

In other news, VP Pat Cotroneo sold 95,000 shares of the company’s stock in a transaction that occurred on Tuesday, August 8th. The stock was sold at an average price of $50.61, for a total transaction of $4,807,950.00. Following the transaction, the vice president now directly owns 173,366 shares of the company’s stock, valued at $8,774,053.26. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider K Peony Yu sold 5,000 shares of the company’s stock in a transaction that occurred on Monday, July 10th. The stock was sold at an average price of $32.98, for a total value of $164,900.00. Following the transaction, the insider now directly owns 216,507 shares in the company, valued at $7,140,400.86. The disclosure for this sale can be found here. Insiders have sold 557,828 shares of company stock worth $26,758,047 over the last ninety days. 14.90% of the stock is owned by insiders.

Several large investors have recently modified their holdings of FGEN. Ameritas Investment Partners Inc. purchased a new stake in FibroGen in the 1st quarter valued at $111,000. Quantbot Technologies LP purchased a new stake in FibroGen in the 2nd quarter valued at $128,000. SG Americas Securities LLC raised its position in FibroGen by 6.5% in the 2nd quarter. SG Americas Securities LLC now owns 6,747 shares of the biopharmaceutical company’s stock valued at $218,000 after buying an additional 412 shares during the last quarter. Amalgamated Bank purchased a new stake in FibroGen in the 2nd quarter valued at $237,000. Finally, BNP Paribas Arbitrage SA raised its position in FibroGen by 589.1% in the 2nd quarter. BNP Paribas Arbitrage SA now owns 7,401 shares of the biopharmaceutical company’s stock valued at $239,000 after buying an additional 6,327 shares during the last quarter. 47.49% of the stock is currently owned by institutional investors.

FibroGen Company Profile

FibroGen, Inc is a science-based biopharmaceutical company discovering and developing a pipeline of first- in-class therapeutics. The Company is focused on fibrosis and hypoxia-inducible factor (HIF) biology and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer.

Analyst Recommendations for FibroGen (NASDAQ:FGEN)

Receive News & Stock Ratings for FibroGen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen Inc and related stocks with our FREE daily email newsletter.